Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Cohn

Showing results (71-80 of 183) with videos related to

Pageof 19
Sort By:
Pediatric Blood & Cancer|October 20, 2023
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastomaOmar R Vayani, Maria E Kaufman, Kelley Moore, et al.
Pediatric Blood & Cancer|May 31, 2020
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectVeronica Moroz, David Machin, Barbara Hero, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|December 5, 2013
Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaborationChaim Kirby, Peter F Ambros, David Billiter, et al.
Oncotarget|October 25, 2016
Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acidsAlexandre Chlenski, Marija Dobratic, Helen R Salwen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group studyLisa A Moreau, Patrick McGrady, Wendy B London, et al.
JAMA Network Open|July 8, 2021
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk NeuroblastomaSkye Balyasny, Sang Mee Lee, Ami V Desai, et al.
Pediatric Blood & Cancer|September 22, 2012
Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progressionAndres Morales La Madrid, Melanie Beglin Nall, Karen Ouyang, et al.
Pediatric Blood & Cancer|March 18, 2014
Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastomaAlissa Martin, Jennifer Schneiderman, Irene B Helenowski, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastomaRiyue Bao, Stefani Spranger, Kyle Hernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group databaseRochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Pageof 19

Showing results (71-80 of 183) with videos related to

Sort By:
Pageof 19
Pediatric Blood & Cancer|October 20, 2023
Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastomaOmar R Vayani, Maria E Kaufman, Kelley Moore, et al.
Pediatric Blood & Cancer|May 31, 2020
The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) projectVeronica Moroz, David Machin, Barbara Hero, et al.
AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|December 5, 2013
Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaborationChaim Kirby, Peter F Ambros, David Billiter, et al.
Oncotarget|October 25, 2016
Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acidsAlexandre Chlenski, Marija Dobratic, Helen R Salwen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group studyLisa A Moreau, Patrick McGrady, Wendy B London, et al.
JAMA Network Open|July 8, 2021
Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk NeuroblastomaSkye Balyasny, Sang Mee Lee, Ami V Desai, et al.
Pediatric Blood & Cancer|September 22, 2012
Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progressionAndres Morales La Madrid, Melanie Beglin Nall, Karen Ouyang, et al.
Pediatric Blood & Cancer|March 18, 2014
Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastomaAlissa Martin, Jennifer Schneiderman, Irene B Helenowski, et al.
Journal for Immunotherapy of Cancer|July 17, 2021
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastomaRiyue Bao, Stefani Spranger, Kyle Hernandez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group databaseRochelle Bagatell, Maja Beck-Popovic, Wendy B London, et al.
Pageof 19